IBJNews

Lilly licenses Xigris rights to new biotech firm

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. has agreed to license the U.S. marketing rights of its slow-selling sepsis drug Xigris to a newly created biotech company that will seek to reinvigorate sales of the medication, the Indianapolis-based drugmaker announced Monday morning.

The new company, BioCritica Inc., will be based in central Indiana and will be jointly owned by Lilly and two private investment firms: New Jersey-based Care Capital LLC and North Carolina-based NovaQuest Capital Management LLC.

The company will be led by David Broecker, who managed Lilly manufacturing operations in Germany and Ireland before becoming CEO of Alkermes Inc., a Massachusetts-based drug development firm.

A “handful” of Lilly employees will leave Lilly to join BioCritica, Broecker said. He expects the company to employ 20 to 25 people by year's end and as many as 70 by 2015.

The deal was structured with help from Indianapolis-based BioCrossroads, a life sciences business development group. Also, the Indiana Economic Development Corp. committed $2.9 million in tax credits and $175,000 in training grants.

BioCritica hopes to be able to do the clinical trial work necessary to develop Xigris for additional uses other than its treatment of severe sepsis in hospital patients. Within Lilly, Xigris was well down the priority list to get time from scientists and other staff.

“It’s a good way for the molecule to get some resources that it might not otherwise be able to get [inside Lilly],” said Lilly spokesman Mark Taylor.

Lilly, which is trying to find new drugs to replace aging blockbusters, has nearly 70 molecules in clinical trials, and is desperately seeking drugs that can produce annual sales of $500 million or more.

Xigris’ low-priority status within Lilly has much to do with its rather paltry sales, which totaled $104 million last year, down 18 percent from the previous year.

Xigris was the first drug Lilly launched after it lost patent protection on its best-seller Prozac in 2001. It is the only drug approved in the United States to fight severe sepsis. Lilly fought a long legal battle over the drug's patent with Massachusetts-based Ariad Pharmaceuticals Inc.

Expectations for the drug were initially huge, with some Wall Street analysts predicting annual sales of $2 billion. But the drug struggled after U.S. regulators approved the drug for a small category of patients, and because hospitals struggled to identify which patients and in which situations the drug was appropriate.

But Broecker hopes a new clinical trial Lilly sponsored, which is scheduled to produce results by year's end, will clear up that confusion.

"We believe if it's favorable, it will allow us to go out and essentially re-energize the marketplace," Broecker said.

BioCritica also plans to license and sell other drugs for use in critical care patients in hospitals.

“We are confident that BioCritica will help realize the full potential for Xigris while working to develop new critical care medicines,” said Lilly CEO John Lechleiter, in a statement.

Lilly did not disclose the financial terms of the deal, nor how much equity it will hold in BioCritica. Tayor said BioCritica will have an option to acquire the international rights to Xigris at a later date.

Taylor said the deal will have minimal impact on Lilly’s work force, since Xigris is manufactured by third-party firms and is sold via a contract sales force. Lilly does and will continue to do the packaging of Xigris.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I am a Lyft driver who is a licensed CDL professional driver. ALL Lyft drivers take pride in providing quality service to the Indianapolis and surrounding areas, and we take the safety of our passengers and the public seriously.(passengers are required to put seat belts on when they get in our cars) We do go through background checks, driving records are checked as are the personal cars we drive, (these are OUR private cars we use) Unlike taxi cabs and their drivers Lyft (and yes Uber) provide passengers with a clean car inside and out, a friendly and courteous driver, and who is dressed appropriately and is groomed appropriately. I go so far as to offer mints, candy and/or small bottle of water to the my customers. It's a mutual respect between driver and passenger. With Best Regards

  2. to be the big fish in the little pond of IRL midwest racin' when yer up against Racin' Gardner

  3. In the first sentance "As a resident of one of these new Carmel Apartments the issue the local governments need to discuss are build quality & price." need a way to edit

  4. As a resident of one of these new Carmel Apartments the issue the local governments need to discuss is build quality & price. First none of these places is worth $1100 for a one bedroom. Downtown Carmel or Keystone at the Crossing in Indy. It doesn't matter. All require you to get in your car to get just about anywhere you need to go. I'm in one of the Carmel apartments now where after just 2.5 short years one of the kitchen cabinet doors is crooked and lawn and property maintenance seems to be lacking my old Indianapolis apartment which cost $300 less. This is one of the new star apartments. As they keep building throughout the area "deals" will start popping up creating shoppers. If your property is falling apart after year 3 what will it look like after year 5 or 10??? Why would one stay here if they could move to a new Broad Ripple in 2 to 3 years or another part of the Far Northside?? The complexes aren't going to let the "poor" move in without local permission so that's not that problem, but it the occupancy rate drops suddenly because the "Young" people moved back to Indy then look out.

  5. Why are you so concerned about Ace hardware? I don't understand why anyone goes there! Every time ive gone in the past, they don't have what I need and I end up going to the big box stores. I understand the service aspect and that they try to be helpful but if they are going to survive I think they might need to carry more specialty parts.

ADVERTISEMENT